Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients

All NewsApril 23, 2026

Novo Nordisk reports phase 3 data showing oral semaglutide reduced HbA1c in adolescents with type 2 diabetes and was well tolerated.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent